MedicaidPrior AuthLow impact
Unloxcyt™ (cosibelimab-ipdl) (New)
Humana·LA · Oncology, Dermatology·Medicaid
Effective date
May 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Unloxcyt (cosibelimab-ipdl), a PD-L1 inhibitor for cutaneous squamous cell carcinoma, effective May 1, 2026 for Louisiana Medicaid. Requires pre-approval for locally advanced/metastatic cases where surgery or radiation isn't curative, and excludes patients who progressed on prior PD-1/PD-L1 inhibitors.
Action Required
By May 1, 2026: Billing team must update prior authorization system to require pre-approval for Unloxcyt (cosibelimab-ipdl) for Louisiana Medicaid patients with cutaneous squamous cell carcinoma. Providers must verify patient meets all four criteria (locally advanced/metastatic disease, not candidate for curative surgery/radiation, monotherapy use) and document exclusion of prior PD-1/PD-L1 inhibitor treatment. Claims without prior authorization will be denied.